Category: Bolt Biotherapeutics

  • Genmab takes aims at immuno-oncology antibody conjugates with Bolt Bio

    Genmab has enlisted the help of Bolt Biotherapeutics to develop a new class of immune-boosting antibody conjugates for cancer in a deal that could be worth up to $880 million. Denmark-based Genmab is paying $10 million upfront to its US counterpart and making a $15 million equity investment to get the project started, funding R&D […]